Previous 10 | Next 10 |
2023-07-14 06:21:00 ET 3 Questions About Penny Stocks: Answered for 2023 Penny stocks, often undervalued by the mainstream investment world, present a unique opportunity for those willing to explore the less trodden paths of the financial markets. As we navigate through 2023, the penn...
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience PR Newswire Phase 2 Bryostatin-1 Severe Cohort secondary and exploratory endpoint...
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities PR Newswire Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients Maintains strong finan...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the t...
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease PR Newswire NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an eme...
Summary Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer’s disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has some effect, and has a unique mechanism of action. Despite a clear po...
Synaptogenix Announces $15 Million Private Placement with Existing Investors PR Newswire Topline data from NIH-supported Phase 2 clinical trial for advanced AD patients expected during the current quarter NEW YORK , Nov. 18, 2022 /PRNewswire/ -- S...
Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 PR Newswire Synaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date Topline data from NIH...
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results PR Newswire Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK , Sept. 28, 2022 /PRNewswire/ -- Synapto...
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data PR Newswire Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury PR Newswire Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in ...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...